Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind Placebo-controlled Study to Demonstrate the Efficacy of PMBL® Sublingual Tablets in Reducing the Incidence of Respiratory Tract Infections in Children Aged 3-12 Years (PIRTIK).

NCT07578012 is registered in ClinicalTrials.gov with Lallemand Pharma AG as lead sponsor.

NCT NCT07578012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07578012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind Placebo-controlled Study to Demonstrate the Efficacy of PMBL® Sublingual Tablets in Reducing the Incidence of Respiratory Tract Infections in Children Aged 3-12 Years (PIRTIK).
Lead sponsor
Lallemand Pharma AG
Phase
Phase 4
Overall status
Recruiting
Start date
June 1, 2026
Completion date
April 30, 2027
Enrollment
224 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

healthy children, respiratory tract infections (rti)